Prognostic nutritional index predicts outcomes in hepatocellular carcinoma treated with atezolizumab and bevacizumab
Background and Aims
The prognostic nutritional index (PNI), calculated from serum albumin and lymphocyte count, reflects a patient’s immune-nutritional status and has been proposed as a prognostic marker in hepatocellular carcinoma (HCC). However, its role in advanced HCC patients treated with atezolizumab plus bevacizumab (Ate/Bev) remains unclear. In this study, we aimed to evaluate the prognostic value of PNI in patients receiving first-line Ate/Bev therapy.
Methods
We retrospectively analyzed 362 patients with unresectable HCC who received Ate/Bev between November 2020 ...